Pulmonary hypertension-specific therapy
PreclinicalSmall molecule
Pulmonary hypertension-specific therapy is one of 9 small molecule programs targeting Chronic Thromboembolic Pulmonary Hypertension. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
10 competitors in Chronic Thromboembolic Pulmonary Hypertension
#DrugCompanyPhaseTrials
1Adempas
BayerPhase 3
Opsumit
Johnson & JohnsonPhase 3
Tracleer
Johnson & JohnsonPhase 3
Letairis
GileadPhase 3
Uptravi
Johnson & JohnsonPhase 3
Treprostinil Sodium
United TherapeuticsPhase 3
N-Acetyl Cyteien
SStanford University
Preclinical
Adempas
BayerPreclinical
Pulmonary hypertension-specific therapy
IIrina E. Chazova
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- IIrina E. Chazova